Ongoing studies evaluating BispAbs in multiple myeloma
| Study . | Population . | Phase . | Treatment . |
|---|---|---|---|
| CD3 × BCMA | |||
| NCT04557098 (MajesTEC-1) | RRMM | 1-2 | Teclistamab |
| NCT04722146 (MajesTEC-2) | RRMM and NDMM | 1b | Teclistamab in combination with
|
| NCT05083169 (MajesTEC-3) | RRMM | 3 randomized | Teclistamab dara vs DPd/DVd |
| NCT04108195 (TRIMM-2) | RRMM | 1b | Teclistamab in combination with
|
| NCT04586426 | RRMM | 1b | Teclistamab in combination with
|
| NCT05243797 (MajesTEC-4) | NDMM (maintenance) | 3 randomized | Teclistamab len vs len |
| NCT05231629 (Master-2) | NDMM | 3 randomized | Teclistamab dara |
| NCT03269136 (MAGNETISMM-1) | RRMM | 1 | Elranatamab |
| NCT04649359 (MAGNETISMM-3) | RRMM | 2 | Elranatamab |
| NCT05090566 (MAGNETISMM-4) | RRMM | 1b-2 | Elranatamab + nirogacestat |
| NCT05020236 (MAGNETISMM-5) | RRMM | 3 | Elranatamab dara vs DPd |
| NCT05137054 | RRMM | 1b | REGN5458 in combination with
|
| NCT03933735 | RRMM | 1 | TNB-383B |
| NCT04184050 | RRMM | 1-2 | HPN217 (trispecific BCMA × CD3 × albumin) |
| NCT04735575 | RRMM | 1-2 | EMB-06 |
| GPRC5D × CD3 | |||
| NCT03399799 (MONUMENTAL-1) | RRMM | 1 | Talquetamab |
| TRIMM-2 NCT04108195 | RRMM | 1b | Talquetamab dara Talquetamab dara pom |
| NCT05050097 (MONUMENTAL-2) | RRMM | 1b | Talquetamab in combination with
|
| FCRH5 × CD3 | |||
| NCT03275103 (GRACE) | RRMM | 1 | Cevostamab |
| CD38 × CD3 | |||
| NCT03309111 | RRMM | 1 | ISB 1342 |
| NCT05011097 | RRMM | 1 | Y150 |
| Study . | Population . | Phase . | Treatment . |
|---|---|---|---|
| CD3 × BCMA | |||
| NCT04557098 (MajesTEC-1) | RRMM | 1-2 | Teclistamab |
| NCT04722146 (MajesTEC-2) | RRMM and NDMM | 1b | Teclistamab in combination with
|
| NCT05083169 (MajesTEC-3) | RRMM | 3 randomized | Teclistamab dara vs DPd/DVd |
| NCT04108195 (TRIMM-2) | RRMM | 1b | Teclistamab in combination with
|
| NCT04586426 | RRMM | 1b | Teclistamab in combination with
|
| NCT05243797 (MajesTEC-4) | NDMM (maintenance) | 3 randomized | Teclistamab len vs len |
| NCT05231629 (Master-2) | NDMM | 3 randomized | Teclistamab dara |
| NCT03269136 (MAGNETISMM-1) | RRMM | 1 | Elranatamab |
| NCT04649359 (MAGNETISMM-3) | RRMM | 2 | Elranatamab |
| NCT05090566 (MAGNETISMM-4) | RRMM | 1b-2 | Elranatamab + nirogacestat |
| NCT05020236 (MAGNETISMM-5) | RRMM | 3 | Elranatamab dara vs DPd |
| NCT05137054 | RRMM | 1b | REGN5458 in combination with
|
| NCT03933735 | RRMM | 1 | TNB-383B |
| NCT04184050 | RRMM | 1-2 | HPN217 (trispecific BCMA × CD3 × albumin) |
| NCT04735575 | RRMM | 1-2 | EMB-06 |
| GPRC5D × CD3 | |||
| NCT03399799 (MONUMENTAL-1) | RRMM | 1 | Talquetamab |
| TRIMM-2 NCT04108195 | RRMM | 1b | Talquetamab dara Talquetamab dara pom |
| NCT05050097 (MONUMENTAL-2) | RRMM | 1b | Talquetamab in combination with
|
| FCRH5 × CD3 | |||
| NCT03275103 (GRACE) | RRMM | 1 | Cevostamab |
| CD38 × CD3 | |||
| NCT03309111 | RRMM | 1 | ISB 1342 |
| NCT05011097 | RRMM | 1 | Y150 |
btz, bortezomib; dara, daratumumab; DPd, daratumumab-pomalidomide-dexamethasone; DVd, daratumumab-bortezomib-dexamethasone; len, lenalidomide; NDMM, newly diagnosed multiple myeloma; pom, pomalidomide.